Should I buy or sell Femasys stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FEMY shares. View FEMY analyst ratings or view top-rated stocks .

What is Femasys' stock price target for 2024?

3 equities research analysts have issued twelve-month price targets for Femasys' stock. Their FEMY share price targets range from $10.00 to $12.00. On average, they predict the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 771.8% from the stock's current price. View analysts price targets for FEMY or view top-rated stocks among Wall Street analysts .

How have FEMY shares performed in 2024?

Femasys' stock was trading at $0.9750 at the start of the year. Since then, FEMY stock has increased by 33.3% and is now trading at $1.30. View the best growth stocks for 2024 here .

Are investors shorting Femasys?

Femasys saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,740,000 shares, an increase of 55.4% from the March 15th total of 1,120,000 shares. Based on an average daily volume of 702,600 shares, the short-interest ratio is presently 2.5 days. Currently, 8.5% of the shares of the company are short sold. View Femasys' Short Interest .

When is Femasys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FEMY earnings forecast .

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) posted its earnings results on Thursday, March, 28th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.30 million. Femasys had a negative trailing twelve-month return on equity of 105.47% and a negative net margin of 1,329.10%.

When did Femasys IPO?

Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading served as the underwriters for the IPO.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FEMY

Femasys (FEMY) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free FEMY Stock Alerts

$1.30

-0.01 (-0.76%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.29
▼
$1.34
50-Day Range: $1.10
▼
$2.22
52-Week Range: $0.25
▼
$4.75

Volume: 121,132 shs
Average Volume: 661,230 shs
Market Capitalization: $28.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.33

Get Femasys alerts:

Femasys MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 771.8% Upside
$11.33 Price Target
Short Interest: Bearish
8.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.88) to ($0.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

677th out of 914 stocks

Surgical & Medical Instruments Industry

69th out of 94 stocks

3.5

Analyst's Opinion

Consensus Rating
Femasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Femasys has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.54% of the float of Femasys has been sold short.
Short Interest Ratio / Days to Cover
Femasys has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Femasys has recently increased by 55.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Femasys does not currently pay a dividend.
Dividend Growth
Femasys does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FEMY.

0.6

News and Social Media Coverage

News Sentiment
Femasys has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Femasys this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Femasys insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.39% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Femasys are expected to grow in the coming year, from ($0.88) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Femasys is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Femasys is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Femasys has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Femasys Stock (NASDAQ:FEMY)

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

FEMY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FEMY Stock News Headlines

April 17, 2024 | msn.com

Femasys (FEMY) Price Target Increased by 5.41% to 9.95

March 31, 2024 | finance.yahoo.com

Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | investorplace.com

FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023

March 28, 2024 | globenewswire.com

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

March 21, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)

March 21, 2024 | globenewswire.com

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

March 21, 2024 | marketwatch.com

Femasys Discloses Positive Data from FemaSeed Trial

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 20, 2024 | finanznachrichten.de

Femasys Inc.: Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility

March 20, 2024 | markets.businessinsider.com

Femasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In Women

March 20, 2024 | globenewswire.com

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

March 13, 2024 | finance.yahoo.com

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

March 9, 2024 | morningstar.com

Thinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?

March 6, 2024 | finanznachrichten.de

Femasys Inc.: Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

March 6, 2024 | globenewswire.com

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

February 28, 2024 | finanznachrichten.de

Femasys Inc.: Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

February 28, 2024 | finance.yahoo.com

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

February 28, 2024 | globenewswire.com

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

February 24, 2024 | benzinga.com

Femasys Stock (NASDAQ:FEMY), Short Interest Report

February 12, 2024 | msn.com

T2 Biosystems, Invivyd among healthcare movers

February 7, 2024 | msn.com

Femasys Welcomes New Chief Commercial Officer Mr. Spector

January 23, 2024 | finance.yahoo.com

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

December 27, 2023 | benzinga.com

Femasys Stock (NASDAQ:FEMY) Dividends: History, Yield and Dates

December 15, 2023 | finance.yahoo.com

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

November 30, 2023 | msn.com

Femasys filed to sell 18.11M shares of common stock for holders

November 30, 2023 | baystreet.ca

Femasys Names New Chief Medical Officer

See More Headlines

Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:FEMY
CUSIP: N/A
CIK: 1339005
Web: www.femasys.com
Phone: 770-500-3910
Fax: N/A
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.33
High Stock Price Target: $12.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +765.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,250,000.00
Net Margins: -1,329.10%
Pretax Margin: -1,328.64%
Return on Equity: -105.47%
Return on Assets: -80.50%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 7.59
Quick Ratio: 7.37

Sales & Book Value

Annual Sales: $1.07 million
Price / Sales: 27.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.85 per share
Price / Book: 1.54

Miscellaneous

Outstanding Shares: 22,100,000
Free Float: 18,477,000
Market Cap: $28.95 million
Optionable: Not Optionable
Beta: -3.00

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Kathy Lee-Sepsick (Age 56)
Founder, President, CEO & Director
Comp: $453.58k
Mr. Dov Elefant (Age 57)
Chief Financial Officer
Comp: $355.72k
Mr. Daniel Scott Currie (Age 60)
COO, Senior VP & Secretary
Comp: $352.55k
Ms. Mary An Merchant J.D.
Ph.D., Vice President of Counsel & Intellectual Property
Dr. Jeffrey Marcus M.D.
M.S., Chief Medical Advisor
Ms. Christine Thomas (Age 51)
Senior VP of Regulatory & Clinical Affairs
Dr. James H. Liu M.D.
Chief Medical Officer
Mr. Richard Spector
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

FEMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Femasys stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings or view top-rated stocks.
What is Femasys' stock price target for 2024?: 3 equities research analysts have issued twelve-month price targets for Femasys' stock. Their FEMY share price targets range from $10.00 to $12.00. On average, they predict the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 771.8% from the stock's current price.
View analysts price targets for FEMY or view top-rated stocks among Wall Street analysts.
How have FEMY shares performed in 2024?: Femasys' stock was trading at $0.9750 at the start of the year. Since then, FEMY stock has increased by 33.3% and is now trading at $1.30.
View the best growth stocks for 2024 here.
Are investors shorting Femasys?: Femasys saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,740,000 shares, an increase of 55.4% from the March 15th total of 1,120,000 shares. Based on an average daily volume of 702,600 shares, the short-interest ratio is presently 2.5 days. Currently, 8.5% of the shares of the company are short sold.
View Femasys' Short Interest.

When is Femasys' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FEMY earnings forecast.
How were Femasys' earnings last quarter?: Femasys Inc. (NASDAQ:FEMY) posted its earnings results on Thursday, March, 28th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.30 million. Femasys had a negative trailing twelve-month return on equity of 105.47% and a negative net margin of 1,329.10%.
When did Femasys IPO?: Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading served as the underwriters for the IPO.
How do I buy shares of Femasys?: Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FEMY) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Femasys (FEMY) Stock Price, News & Analysis

Femasys MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Femasys Stock (NASDAQ:FEMY)

FEMY Stock Price History

FEMY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

FEMY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™